Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 12

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 12
---
 foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates in our initial and any additional indications as well as for other product candidates. 3 Table of Contents We anticipate that our expenses will increase substantially if and as we:

| • | continue to develop and conduct clinical trials, including in expanded geographies such as the United States, for our GH001 and GH002 product candidates for our initial indications and any additional indications; |

| • | continue both the technical development and expansion of our external manufacturing capabilities for our current product candidates GH001 and GH002 and of the medical devices required to deliver these product candidates, such as our 
 proprietary aerosol delivery device for GH001;                                                                                                                                                                                           |

| • | initiate and continue research and development, including technical, nonclinical, clinical, and discovery efforts for any future product candidates; |

| • | seek to identify additional product candidates; |

| • | seek regulatory approvals for our product candidates GH001 and GH002, including the medical devices required to deliver these product candidates, such as our proprietary aerosol delivery device for GH001, or any other product candidates 
 that successfully complete clinical development;                                                                                                                                                                                             |

| • | progress any nonclinical programs and any other work that may be required to lift the clinical hold imposed by the FDA on the study we proposed in our IND for GH001; |

| • | add operational, financial and management information systems and personnel, including personnel to support our product candidate and device development and help us comply with our obligations as a public company; |

| • | hire and retain additional personnel, such as clinical, quality control, scientific, commercial, sales, marketing and administrative personnel; |

| • | continue to prepare, file, prosecute, maintain, protect and enforce our intellectual property rights and claims; |

| • | establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the future to commercialize various products for which we may obtain regulatory approval; |

| • | comply with ongoing regulatory requirements for products approved for commercial sale, if ever; |

| • | adapt to ongoing changes in global economic conditions, including but not limited to changes in tariffs and trade barriers, heightened inflation, disruptions in global supply chains and labor markets and geopolitical risks and global 
 hostilities, including any direct or indirect economic impacts resulting from conflicts in Eastern Europe and the Middle East and any resulting conflicts in such regions, or increased tensions between China and Taiwan;                |

| • | acquire